{"gene":"CD44","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1992,"finding":"CD44 mediates the endocytosis and lysosomal degradation of hyaluronan; antibodies against CD44 block HA uptake and internalization in fibroblasts and macrophages, and agents blocking lysosomal acidification (chloroquine, NH4Cl) inhibit subsequent HA degradation. CD44 itself lacks intrinsic degradative activity, as isolated membrane preparations containing CD44 do not break down HA.","method":"Isotopic labeling of hyaluronan, molecular-sieve chromatography, antibody blocking, fluorescein-tagged HA internalization assay, lysosomal inhibitors","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (radiolabeled substrate degradation assay, fluorescent internalization, antibody blocking, pharmacological inhibition) in two cell types; replicated internally with rigorous controls","pmids":["1370836"],"is_preprint":false},{"year":1996,"finding":"N-linked glycosylation of CD44 is required for hyaluronan binding; tunicamycin abolishes HA-mediated cell adhesion, while mutation of any one of five N-linked glycosylation sites within the HA-recognition domain abrogates binding. Mutation of Ser-Gly motifs providing glycosaminoglycan attachment sites in the membrane-proximal domain also impairs HA binding, indicating that specific glycosylation patterns maintain the HA-recognition domain in the appropriate conformation.","method":"Tunicamycin treatment, deoxymannojirimycin treatment, site-directed mutagenesis of N-linked glycosylation sites, stable transfection of CD44 mutants, cell adhesion assay on HA-coated substrate","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic mutagenesis of all five glycosylation sites combined with pharmacological inhibitors and functional adhesion readout in stably transfected cells","pmids":["8601595"],"is_preprint":false},{"year":2000,"finding":"HA binding at the cell surface involves multivalent interactions dependent on HA size, CD44 density, and CD44 activation state. Monovalent binding requires 6–18 sugar residues; divalent binding begins at ~20–38 residues. An inducing anti-CD44 mAb (IRAWB14) dramatically slows HA dissociation from the cell surface (without affecting binding kinetics), revealing that CD44 activation state is a key regulator of HA retention.","method":"Competitive inhibition assay with fluorescein-conjugated HA, defined-size HA oligomers, kinetic binding/dissociation studies, monoclonal antibody activation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — quantitative binding assay with defined oligomer sizes and kinetic measurements, multiple orthogonal approaches in one study","pmids":["10871609"],"is_preprint":false},{"year":2003,"finding":"CD44 undergoes ectodomain shedding catalyzed by ADAM10 (a disintegrin and metalloproteinase 10), which is augmented by CD44 ligation and Rac1-mediated cytoskeletal rearrangement. CD44 engagement activates Rac1, causing redistribution of CD44 to membrane ruffles at the leading edge; ADAM10 knockdown by RNAi suppresses CD44 cleavage. CD44 cleavage promotes tumor cell migration and invasion.","method":"Metalloproteinase inhibitors (KB-R7785, TIMP-1, TIMP-2), RNA interference of ADAM10, FRET-based visualization of active Rac1 in living cells, cell morphology/actin cytoskeleton analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — RNAi-based identification of ADAM10, FRET-based live-cell Rac1 activation, pharmacological inhibitors with functional migration readout; multiple orthogonal methods","pmids":["14623895"],"is_preprint":false},{"year":2004,"finding":"CD44 undergoes sequential proteolytic cleavages: (1) ectodomain shedding regulated by metalloproteinases and triggered by multiple stimuli, which controls cell attachment to and migration on HA matrix; (2) subsequent intramembranous cleavage by presenilin-dependent γ-secretase, generating a CD44 intracellular domain (CD44-ICD) that translocates to the nucleus and activates transcription.","method":"Biochemical analysis of cleavage fragments, γ-secretase inhibition, nuclear translocation assays","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — review synthesizing experimental findings from multiple laboratories; mechanistic details (γ-secretase, nuclear translocation) are cited from experimental studies but abstract-level detail is limited","pmids":["15596040"],"is_preprint":false},{"year":2006,"finding":"CD44 functions as a primary phagocytic receptor: macrophages expressing CD44 efficiently engulf HA-coated beads and anti-CD44-opsonized erythrocytes via a mechanism involving Syk kinase, Rac1, and PI3-kinase, and inducing phagocyte oxidase activation. CD44-deficient macrophages cannot perform this phagocytosis, and the pathway is independent of Fc receptors.","method":"Hyaluronan-coated beads, anti-CD44-opsonized erythrocyte engulfment, CD44 knockout macrophages, immunoprecipitation, pharmacological inhibition (Syk, PI3K), genetic deletion","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout macrophages, pharmacological inhibitors, and multiple substrates used together; clear primary receptor function demonstrated with rigorous controls","pmids":["16455948"],"is_preprint":false},{"year":2008,"finding":"CD44 directly associates with TLR2 upon stimulation by the TLR2 ligand zymosan and negatively regulates TLR-mediated NF-κB activation and proinflammatory cytokine production in vivo. The cytoplasmic domain of CD44 is required for this regulatory effect on TLR signaling.","method":"Co-immunoprecipitation of CD44 and TLR2, cytoplasmic domain deletion constructs, in vivo inflammation models, cytokine measurement","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct association shown by co-IP, domain requirement demonstrated by cytoplasmic deletion, but single-lab study","pmids":["18322236"],"is_preprint":false},{"year":2010,"finding":"CD44 promotes survival of effector Th1 cells by limiting Fas-mediated apoptosis, thereby enabling memory Th1 cell generation. CD44 ligation engages the PI3K-Akt signaling pathway in Th1 cells. This survival function is Th1-specific and is not observed in Th2, Th17, or CD8+ T cells despite equivalent CD44 expression.","method":"CD44-deficient mice, Th1/Th2/Th17/CD8+ T cell subset analysis, apoptosis assays, PI3K-Akt signaling pathway measurement","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with precise subset-specific phenotype, signaling pathway identified, replicated across multiple T cell subsets as internal controls","pmids":["20079666"],"is_preprint":false},{"year":2010,"finding":"CD44 interacts with IQGAP1 (an actin-binding protein) via its intracellular C-terminus; an endogenous CD44-IQGAP1 complex was demonstrated in normal and transformed cell types, linking CD44 to cytoskeletal reorganization.","method":"Peptide-based pull-down with phosphorylated/non-phosphorylated CD44 C-terminal peptides, MALDI-TOF mass spectrometry identification, co-immunoprecipitation of endogenous complex","journal":"IUBMB life","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pull-down identified partners; endogenous complex confirmed by Co-IP in multiple cell types; single lab but two orthogonal methods","pmids":["21117172"],"is_preprint":false},{"year":2014,"finding":"CD44 acts as a positive regulator of the Wnt receptor complex by physically associating with LRP6 upon Wnt stimulation and modulating LRP6 membrane localization. CD44 knockdown decreases, and overexpression increases, Wnt/β-catenin signaling activity. Epistasis experiments place CD44 function at the level of LRP6. CD44 regulates Wnt target gene expression (tcf-4 and en-2) in Xenopus brain development.","method":"Co-immunoprecipitation of CD44 and LRP6, CD44 knockdown/overexpression, Wnt reporter assay, epistasis analysis, CD44 morpholino knockdown in Xenopus laevis embryos","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, genetic epistasis, in vivo Xenopus morphant validation, and dose-dependent reporter assays provide multiple orthogonal lines of evidence","pmids":["25301071"],"is_preprint":false},{"year":2014,"finding":"CD44 signals through RhoA to regulate YAP expression and nuclear localization in the Hippo pathway. CD44 knockdown reduces RhoA expression, and constitutively active RhoA (RhoA-V14) rescues the YAP decrease caused by CD44 knockdown. CD44 knockdown also reduces expression of YAP target genes (CTGF, Cyr61, EDN1) and promotes apoptosis while inhibiting proliferation and migration.","method":"RNAi knockdown of CD44, overexpression of constitutively active RhoA, qRT-PCR of YAP targets, cell proliferation/apoptosis/migration assays","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis by rescue with constitutively active RhoA, consistent phenotypic readouts; single lab","pmids":["25101858"],"is_preprint":false},{"year":2015,"finding":"CD44 regulates pancreatic cancer invasion through a CD44→Snail1→MT1-MMP (MMP14) axis: CD44 drives expression of the EMT transcription factor Snail1, which in turn regulates membrane-bound MT1-MMP expression required for invasion. Loss of CD44 reduces Snail1 and MT1-MMP levels and abolishes invasion in vitro and in vivo.","method":"CD44 knockdown/overexpression in pancreatic cancer cells, western blot for Snail1 and MT1-MMP, invasion assays, in vivo tumor models","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined signaling axis with multiple molecular readouts and in vivo confirmation; single lab","pmids":["25566991"],"is_preprint":false},{"year":2017,"finding":"Atomistic molecular dynamics simulations reveal that hyaluronan binds CD44's hyaluronan-binding domain via three topographically distinct binding modes. The crystallographic mode is the strongest; two metastable modes are more frequently observed in unbiased simulations. CD44 can diffuse along HA in a 1D manner when attached via weaker modes, potentially influencing CD44 aggregation kinetics relevant to signaling.","method":"Atomistic molecular dynamics simulations with multiple independent runs, comparison to X-ray crystallographic binding mode","journal":"PLoS computational biology","confidence":"Low","confidence_rationale":"Tier 4 / Moderate — computational/simulation only, no direct experimental validation of the two new binding modes; replicated within computational framework","pmids":["28715483"],"is_preprint":false},{"year":2018,"finding":"GPNMB attenuates astrocyte inflammatory responses through CD44: recombinant GPNMB reduces cytokine-induced iNOS, nitric oxide, ROS, and IL-6 in astrocytes, and this anti-inflammatory effect is abolished in CD44 knockout astrocytes, establishing CD44 as the required receptor for GPNMB-mediated neuroprotection.","method":"Recombinant GPNMB treatment, CD44 knockout primary astrocytes, qPCR, nitric oxide and ROS measurement, immunofluorescence","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CD44 KO used to confirm receptor requirement; multiple inflammatory markers measured; single lab","pmids":["29519253"],"is_preprint":false},{"year":2020,"finding":"CD44 mediates endocytosis of iron-bound hyaluronates, providing an alternative iron-uptake mechanism in mesenchymal-state cells. Internalized iron acts as a metal catalyst to demethylate repressive histone marks (H3K9me2/me3 and H3K27me3), thereby governing expression of mesenchymal genes and enabling epigenetic plasticity. CD44 expression is itself transcriptionally upregulated by nuclear iron through a positive feedback loop, in contrast to the negative iron regulation of transferrin receptor.","method":"Iron-bound hyaluronate endocytosis assays in tumorigenic cell lines and primary cancer cells, histone methylation profiling, small-molecule interference with iron homeostasis, EMT induction assays","journal":"Nature chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic pathway from CD44 endocytosis to epigenetic modification demonstrated with multiple orthogonal approaches (endocytosis assays, histone marks, gene expression, primary cancer cells and tumors), single lab with rigorous methods","pmids":["32747755"],"is_preprint":false},{"year":2021,"finding":"CD44 regulates membrane accumulation of COL17A1 (collagen XVII) in multilayered transformed epithelia. CD44 and COL17A1 accumulate in oncogene (RasV12, Src, ErbB2)-transformed epithelial cells, suppress mitochondrial ROS production, and thereby promote resistance to ferroptosis-mediated cell death during cell extrusion, enabling clonal expansion of transformed cells.","method":"Plasma membrane protein screening, COL17A1 knockout in RasV12 cells, metabolome analysis, ROS and mitochondrial membrane potential measurement, in vitro and in vivo multilayered epithelial models","journal":"Current biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CD44's specific role in COL17A1 membrane accumulation defined, linked to ROS/ferroptosis resistance by KO and metabolomics; single lab with multiple orthogonal approaches","pmids":["34087104"],"is_preprint":false},{"year":2012,"finding":"CD44 is required for Kras-mediated MAPK signaling and lung adenocarcinoma formation in vivo: deletion of CD44 in a KrasG12D mouse model attenuates MAPK pathway activation, reduces tumor cell proliferation, decreases lung adenocarcinoma formation, and prolongs survival.","method":"Cre-mediated KrasG12D lung cancer mouse model with CD44 deletion, MAPK signaling assays, tumor burden quantification, survival analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic epistasis placing CD44 upstream of MAPK in Kras-driven cancer; single lab","pmids":["23208496"],"is_preprint":false},{"year":1995,"finding":"CD44 engagement (by HA or anti-CD44 mAbs) inhibits apoptosis induced by anti-CD3 mAbs and dexamethasone in T cells, but not UV-induced (p53-dependent) apoptosis, without upregulating Bcl-2 or affecting proliferation. This places CD44 as a survival signal that specifically counteracts TCR- and glucocorticoid-mediated apoptotic pathways.","method":"Anti-CD44 antibody and HA ligation, DNA fragmentation assay, apoptosis quantification, Bcl-2 expression analysis in 3DO T-cell line","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific pathway positioning (anti-CD3/dexamethasone vs. UV/p53) with multiple stimuli and Bcl-2 exclusion; single lab","pmids":["7545465"],"is_preprint":false},{"year":2021,"finding":"CD44 depletion (CRISPR/Cas9 KO) in GBM cells impairs proliferation (decreased Ki67, reduced CREB phosphorylation, elevated p16), decreases stemness, and induces senescence. γ-Secretase inhibition (DAPT, blocking CD44-ICD release) phenocopies some of these effects, suggesting CD44-ICD-dependent transcriptional regulation. CD44 KO also deregulates HAS2 and hyaluronan synthesis, and downregulation of HAS2 reduces CD44 protein levels, indicating a CD44/hyaluronan positive feedback circuit.","method":"CRISPR/Cas9 CD44 knockout, γ-secretase inhibitor DAPT, RNA sequencing, Ki67 staining, p16/CREB phosphorylation western blot, sphere formation assays","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with RNA-seq and multiple molecular readouts; γ-secretase inhibitor confirms ICD-dependent transcription; single lab","pmids":["35954411"],"is_preprint":false},{"year":2021,"finding":"Androgen receptor (AR) directly represses CD44 transcription through a novel androgen response element silencer in the CD44 locus, as demonstrated by CRISPR-based mutagenesis of the ARE. AR ChIP-seq and transcriptomics confirmed CD44 as an AR-regulated gene, and AR and CD44 expression are inversely correlated in human bladder tumors.","method":"AR ChIP sequencing, transcriptomics, CRISPR mutagenesis of androgen response elements, pooled shRNA/ORF functional genomics screens, human tumor expression correlation","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — CRISPR ARE mutagenesis directly establishes causal silencer element; supported by ChIP-seq and transcriptomics; single lab with multiple rigorous approaches","pmids":["33687952"],"is_preprint":false}],"current_model":"CD44 is a transmembrane glycoprotein that functions as the primary cell surface receptor for hyaluronan, mediating HA endocytosis and lysosomal degradation, and whose HA-binding capacity is regulated by cell-type-specific N-linked and O-linked glycosylation; CD44 undergoes sequential ectodomain shedding (by ADAM10, augmented by Rac1-mediated cytoskeletal rearrangement) and intramembranous γ-secretase cleavage releasing a nuclear ICD that activates transcription; it acts as a co-receptor for LRP6 in Wnt signaling, associates with TLR2 to suppress NF-κB-mediated inflammation, signals through RhoA to regulate YAP/Hippo output, promotes Th1 cell survival via PI3K-Akt/Fas pathway suppression, drives pancreatic cancer invasion through a Snail1→MT1-MMP axis, supports Kras-MAPK signaling in lung adenocarcinoma, mediates phagocytosis via Syk/Rac1/PI3K, and orchestrates iron endocytosis via iron-bound hyaluronates to catalyze histone demethylation and epigenetic plasticity in mesenchymal-state cancer cells."},"narrative":{"mechanistic_narrative":"CD44 is a transmembrane glycoprotein that serves as the principal cell-surface receptor for hyaluronan (HA), mediating HA endocytosis and routing it to lysosomes for degradation, although the protein itself has no intrinsic catalytic activity toward HA [PMID:1370836]. HA recognition is conformationally gated by glycosylation: N-linked glycans at multiple sites within the HA-recognition domain, together with membrane-proximal glycosaminoglycan attachment motifs, are required for binding, and the avidity of the interaction scales with HA size, receptor density, and an inducible activation state that controls ligand retention [PMID:8601595, PMID:10871609]. CD44 transduces these adhesive cues into intracellular signaling and is regulated by sequential proteolysis: ADAM10-catalyzed ectodomain shedding, augmented by CD44 ligation and Rac1-driven cytoskeletal remodeling, is followed by γ-secretase intramembrane cleavage to liberate a CD44 intracellular domain (CD44-ICD) that enters the nucleus and activates transcription [PMID:14623895, PMID:15596040]. Through its cytoplasmic tail CD44 couples to cytoskeletal and signaling machinery—binding IQGAP1, signaling via RhoA to sustain YAP/Hippo output, and engaging Syk/Rac1/PI3K to act as a phagocytic receptor independent of Fc receptors [PMID:16455948, PMID:21117172, PMID:25101858]. CD44 functions as a Wnt co-receptor by associating with and positioning LRP6 [PMID:25301071], suppresses TLR2-driven NF-κB inflammation via its cytoplasmic domain [PMID:18322236], and promotes lymphocyte survival by engaging PI3K-Akt to limit Fas-mediated apoptosis [PMID:20079666, PMID:7545465]. In cancer, CD44 supports Kras-MAPK-driven lung adenocarcinoma, drives invasion through a Snail1→MT1-MMP axis, sustains stemness and proliferation through CD44-ICD-dependent transcription, and orchestrates endocytosis of iron-bound hyaluronates that catalyzes histone demethylation to enforce mesenchymal epigenetic plasticity through an iron-CD44 positive feedback loop [PMID:25566991, PMID:32747755, PMID:23208496, PMID:35954411]. CD44 itself is transcriptionally repressed by the androgen receptor through a defined androgen-response-element silencer [PMID:33687952].","teleology":[{"year":1992,"claim":"Established CD44's core physiological function—whether the HA receptor merely binds HA or actively clears it—by showing it drives HA internalization and lysosomal degradation without itself being catalytic.","evidence":"Radiolabeled and fluorescent HA uptake/degradation assays with antibody blocking and lysosomal inhibitors in fibroblasts and macrophages","pmids":["1370836"],"confidence":"High","gaps":["Did not define the molecular determinants of HA binding affinity","Mechanism coupling surface binding to internalization not resolved"]},{"year":1996,"claim":"Resolved why HA-binding capacity varies between cell types by demonstrating that N-linked glycosylation and GAG-attachment motifs maintain the HA-recognition domain in a binding-competent conformation.","evidence":"Tunicamycin treatment plus systematic site-directed mutagenesis of glycosylation sites with HA-adhesion readout in transfectants","pmids":["8601595"],"confidence":"High","gaps":["Structural basis of the conformational requirement not directly determined","Cell-type-specific glycosylation enzymes not identified"]},{"year":2000,"claim":"Quantified how CD44 retains HA by showing multivalent, size-dependent binding and an inducible activation state that slows ligand dissociation, distinguishing avidity control from affinity.","evidence":"Competitive binding with defined HA oligomers and kinetic dissociation studies, plus activating mAb","pmids":["10871609"],"confidence":"High","gaps":["Molecular nature of the activation state not defined","In vivo relevance of multivalency not established"]},{"year":2003,"claim":"Identified the protease and cytoskeletal trigger for CD44 ectodomain release, linking receptor ligation to ADAM10-dependent shedding and tumor cell migration.","evidence":"ADAM10 RNAi, metalloproteinase inhibitors, and FRET imaging of Rac1 activation with migration assays","pmids":["14623895"],"confidence":"High","gaps":["Did not address downstream fate of the shed ectodomain or the membrane-retained stub"]},{"year":2004,"claim":"Placed shedding in a regulated intramembrane proteolysis sequence, establishing that γ-secretase releases a transcriptionally active CD44-ICD after ectodomain cleavage.","evidence":"Biochemical cleavage analysis, γ-secretase inhibition, and nuclear translocation assays (review-level synthesis)","pmids":["15596040"],"confidence":"Medium","gaps":["Direct transcriptional targets of CD44-ICD not enumerated here","Review-level detail; primary mechanistic data limited"]},{"year":2006,"claim":"Demonstrated CD44 acts as a bona fide phagocytic receptor, defining a Syk/Rac1/PI3K signaling route distinct from Fc-receptor phagocytosis.","evidence":"HA-bead and anti-CD44-opsonized erythrocyte engulfment in CD44-knockout macrophages with Syk/PI3K inhibitors","pmids":["16455948"],"confidence":"High","gaps":["Direct biochemical link between CD44 tail and Syk recruitment not shown","Physiological clearance targets in vivo not defined"]},{"year":2008,"claim":"Revealed an immunoregulatory function by showing CD44 physically associates with TLR2 and dampens NF-κB-driven inflammation through its cytoplasmic domain.","evidence":"Co-IP of CD44/TLR2, cytoplasmic-domain deletion constructs, and in vivo cytokine measurement","pmids":["18322236"],"confidence":"Medium","gaps":["Single-lab study without reciprocal validation across systems","Cytoplasmic effector mediating NF-κB suppression unidentified"]},{"year":2010,"claim":"Defined a subset-specific survival role, showing CD44 engages PI3K-Akt to limit Fas-mediated apoptosis and enable Th1 memory generation.","evidence":"CD44-deficient mice with Th1/Th2/Th17/CD8 subset comparison and apoptosis/PI3K-Akt readouts","pmids":["20079666"],"confidence":"High","gaps":["Why the survival function is Th1-restricted despite equal expression unexplained"]},{"year":2010,"claim":"Connected CD44's cytoplasmic tail to the actin cytoskeleton by identifying an endogenous CD44-IQGAP1 complex.","evidence":"Phospho/non-phospho C-terminal peptide pull-down with MS identification and Co-IP of endogenous complex","pmids":["21117172"],"confidence":"Medium","gaps":["Functional consequence of the interaction not tested","Phosphorylation dependence not resolved functionally"]},{"year":2014,"claim":"Established CD44 as a Wnt pathway co-receptor acting at the level of LRP6 to tune β-catenin signaling.","evidence":"Reciprocal Co-IP, knockdown/overexpression reporter assays, epistasis, and Xenopus morphant validation","pmids":["25301071"],"confidence":"High","gaps":["Mechanism by which CD44 controls LRP6 membrane localization not defined"]},{"year":2014,"claim":"Linked CD44 to Hippo output by showing it signals through RhoA to maintain YAP expression and nuclear localization.","evidence":"CD44 RNAi with constitutively active RhoA rescue and YAP-target qRT-PCR plus phenotypic assays","pmids":["25101858"],"confidence":"Medium","gaps":["How CD44 activates RhoA not established","Single-lab study"]},{"year":2012,"claim":"Provided in vivo genetic evidence that CD44 is required for Kras-MAPK signaling and lung adenocarcinoma formation.","evidence":"CD44 deletion in a KrasG12D lung cancer mouse model with MAPK, tumor burden, and survival analysis","pmids":["23208496"],"confidence":"Medium","gaps":["Biochemical step linking CD44 to MAPK activation undefined","Single-lab study"]},{"year":2015,"claim":"Defined a pro-invasive signaling axis, placing CD44 upstream of Snail1-driven MT1-MMP expression in pancreatic cancer.","evidence":"CD44 knockdown/overexpression with Snail1/MT1-MMP western blots, invasion assays, and in vivo tumor models","pmids":["25566991"],"confidence":"Medium","gaps":["Mechanism by which CD44 induces Snail1 not defined","Single-lab study"]},{"year":1995,"claim":"Positioned CD44 as a selective anti-apoptotic signal that counteracts TCR- and glucocorticoid-induced but not p53-dependent death.","evidence":"Anti-CD44/HA ligation with DNA fragmentation and Bcl-2 analysis in a T-cell line","pmids":["7545465"],"confidence":"Medium","gaps":["Downstream survival effector not identified (Bcl-2 excluded)","Single cell-line system"]},{"year":2018,"claim":"Identified CD44 as the required receptor for GPNMB-mediated anti-inflammatory neuroprotection in astrocytes.","evidence":"Recombinant GPNMB on CD44-knockout primary astrocytes with iNOS/NO/ROS/IL-6 readouts","pmids":["29519253"],"confidence":"Medium","gaps":["Direct CD44-GPNMB binding not demonstrated","Downstream signaling not mapped"]},{"year":2020,"claim":"Uncovered a non-canonical role linking CD44 endocytosis to the epigenome, showing iron-bound HA uptake catalyzes histone demethylation and drives mesenchymal plasticity through an iron-CD44 feedback loop.","evidence":"Iron-HA endocytosis assays, histone methylation profiling, iron-homeostasis perturbation, and EMT assays in cancer cells and tumors","pmids":["32747755"],"confidence":"High","gaps":["Specific demethylases catalyzing the marks not identified","Mechanism of nuclear iron delivery from endosome unresolved"]},{"year":2021,"claim":"Tied CD44-ICD transcriptional output to glioblastoma stemness and senescence escape, and linked CD44 to a HAS2/hyaluronan feedback circuit.","evidence":"CRISPR CD44 knockout with RNA-seq, DAPT γ-secretase inhibition, and proliferation/stemness/senescence assays","pmids":["35954411"],"confidence":"Medium","gaps":["Direct CD44-ICD target genes not defined","Single-lab study"]},{"year":2021,"claim":"Defined a role for CD44 in transformed-cell survival by controlling COL17A1 membrane accumulation and suppressing mitochondrial-ROS-driven ferroptosis during cell extrusion.","evidence":"Plasma-membrane proteomics, COL17A1 knockout in RasV12 cells, metabolomics, and ROS/ferroptosis assays","pmids":["34087104"],"confidence":"Medium","gaps":["Mechanism by which CD44 stabilizes COL17A1 at the membrane not defined","Single-lab study"]},{"year":2021,"claim":"Established upstream transcriptional control of CD44, identifying an androgen-receptor silencer element that directly represses CD44 expression.","evidence":"AR ChIP-seq, transcriptomics, CRISPR mutagenesis of the androgen response element, and tumor expression correlation","pmids":["33687952"],"confidence":"High","gaps":["Functional consequence of AR-driven CD44 loss in vivo not fully defined"]},{"year":null,"claim":"How CD44's diverse, context-specific signaling outputs (Wnt, Hippo, MAPK, TLR, phagocytosis, epigenetic plasticity) are selected by a single short cytoplasmic tail in a given cell type remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking ligand/glycosylation state to downstream pathway choice","Structural basis of CD44-ICD transcriptional activity uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[0,5,13]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[1,2]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[6,9,7]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[8,3]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,3,9]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,18]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[9,10,16]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5,6,7]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[0,14]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[11,16,18]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[14]}],"complexes":[],"partners":["LRP6","TLR2","IQGAP1","ADAM10","COL17A1","GPNMB"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P16070","full_name":"CD44 antigen","aliases":["CDw44","Epican","Extracellular matrix receptor III","ECMR-III","GP90 lymphocyte homing/adhesion receptor","HUTCH-I","Heparan sulfate proteoglycan","Hermes antigen","Hyaluronate receptor","Phagocytic glycoprotein 1","PGP-1","Phagocytic glycoprotein I","PGP-I"],"length_aa":742,"mass_kda":81.5,"function":"Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment (PubMed:16541107, PubMed:19703720, PubMed:22726066). Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, hematopoiesis, inflammation and response to bacterial infection (PubMed:7528188). Engages, through its ectodomain, extracellular matrix components such as hyaluronan/HA, collagen, growth factors, cytokines or proteases and serves as a platform for signal transduction by assembling, via its cytoplasmic domain, protein complexes containing receptor kinases and membrane proteases (PubMed:18757307, PubMed:23589287). Such effectors include PKN2, the RhoGTPases RAC1 and RHOA, Rho-kinases and phospholipase C that coordinate signaling pathways promoting calcium mobilization and actin-mediated cytoskeleton reorganization essential for cell migration and adhesion (PubMed:15123640). Upon interaction with LGALS9 ligand, activates downstream signaling components including LCK, ERK and MAPK to promotes NK cell activation (PubMed:37006235) (Microbial infection) Promotes foot-and-mouth disease virus internalization via macropinocytosis","subcellular_location":"Cell membrane; Cell projection, microvillus; Secreted","url":"https://www.uniprot.org/uniprotkb/P16070/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CD44","classification":"Not Classified","n_dependent_lines":30,"n_total_lines":1208,"dependency_fraction":0.024834437086092714},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CD44","total_profiled":1310},"omim":[{"mim_id":"620969","title":"ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE IVb; CDAN4B","url":"https://www.omim.org/entry/620969"},{"mim_id":"617515","title":"RHOMBOID DOMAIN-CONTAINING 1; RHBDD1","url":"https://www.omim.org/entry/617515"},{"mim_id":"617514","title":"IMMUNODEFICIENCY 52; IMD52","url":"https://www.omim.org/entry/617514"},{"mim_id":"617076","title":"FK506-BINDING PROTEIN-LIKE; FKBPL","url":"https://www.omim.org/entry/617076"},{"mim_id":"613673","title":"ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE IVa; CDAN4A","url":"https://www.omim.org/entry/613673"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Golgi apparatus","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"salivary gland","ntpm":469.7}],"url":"https://www.proteinatlas.org/search/CD44"},"hgnc":{"alias_symbol":["IN","MC56","Pgp1","PGP-1","CD44R","HCELL","CSPG8","Hermes-1","CDw44","HUTCH-1","HUTCH-I","ECM-III","H-CAM"],"prev_symbol":["MIC4","MDU2","MDU3"]},"alphafold":{"accession":"P16070","domains":[{"cath_id":"3.10.100.10","chopping":"17-125_133-165","consensus_level":"medium","plddt":95.9503,"start":17,"end":165}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P16070","model_url":"https://alphafold.ebi.ac.uk/files/AF-P16070-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P16070-F1-predicted_aligned_error_v6.png","plddt_mean":53.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CD44","jax_strain_url":"https://www.jax.org/strain/search?query=CD44"},"sequence":{"accession":"P16070","fasta_url":"https://rest.uniprot.org/uniprotkb/P16070.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P16070/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P16070"}},"corpus_meta":[{"pmid":"8379464","id":"PMC_8379464","title":"CD44 and its interaction with extracellular matrix.","date":"1993","source":"Advances in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8379464","citation_count":999,"is_preprint":false},{"pmid":"25999946","id":"PMC_25999946","title":"Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25999946","citation_count":668,"is_preprint":false},{"pmid":"2406365","id":"PMC_2406365","title":"Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures.","date":"1990","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2406365","citation_count":596,"is_preprint":false},{"pmid":"10694938","id":"PMC_10694938","title":"CD44 cell adhesion molecules.","date":"1999","source":"Molecular pathology : MP","url":"https://pubmed.ncbi.nlm.nih.gov/10694938","citation_count":540,"is_preprint":false},{"pmid":"12484499","id":"PMC_12484499","title":"CD44 in cancer.","date":"2002","source":"Critical reviews in clinical laboratory sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12484499","citation_count":462,"is_preprint":false},{"pmid":"7507492","id":"PMC_7507492","title":"Expression and modulation of CD44 variant isoforms in humans.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7507492","citation_count":430,"is_preprint":false},{"pmid":"11325633","id":"PMC_11325633","title":"A crucial role for CD44 in inflammation.","date":"2001","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11325633","citation_count":391,"is_preprint":false},{"pmid":"20303742","id":"PMC_20303742","title":"CD44, a therapeutic target for metastasising tumours.","date":"2010","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/20303742","citation_count":379,"is_preprint":false},{"pmid":"34944493","id":"PMC_34944493","title":"CD44: A Multifunctional Mediator of Cancer Progression.","date":"2021","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/34944493","citation_count":349,"is_preprint":false},{"pmid":"1370836","id":"PMC_1370836","title":"The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan.","date":"1992","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/1370836","citation_count":343,"is_preprint":false},{"pmid":"10871609","id":"PMC_10871609","title":"Hyaluronan binding by cell surface CD44.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10871609","citation_count":340,"is_preprint":false},{"pmid":"15596040","id":"PMC_15596040","title":"Mechanism and biological significance of CD44 cleavage.","date":"2004","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/15596040","citation_count":325,"is_preprint":false},{"pmid":"20008845","id":"PMC_20008845","title":"Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/20008845","citation_count":289,"is_preprint":false},{"pmid":"17079438","id":"PMC_17079438","title":"Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17079438","citation_count":283,"is_preprint":false},{"pmid":"32747755","id":"PMC_32747755","title":"CD44 regulates epigenetic plasticity by mediating iron endocytosis.","date":"2020","source":"Nature chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32747755","citation_count":231,"is_preprint":false},{"pmid":"12796473","id":"PMC_12796473","title":"The liberation of CD44.","date":"2003","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12796473","citation_count":214,"is_preprint":false},{"pmid":"27640754","id":"PMC_27640754","title":"CD44: More than a mere stem cell marker.","date":"2016","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27640754","citation_count":194,"is_preprint":false},{"pmid":"35249813","id":"PMC_35249813","title":"The membrane receptor CD44: novel insights into metabolism.","date":"2022","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/35249813","citation_count":176,"is_preprint":false},{"pmid":"11950588","id":"PMC_11950588","title":"The hyaluronan receptor, CD44.","date":"2002","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11950588","citation_count":171,"is_preprint":false},{"pmid":"7509720","id":"PMC_7509720","title":"Expression of CD44 in human lung tumors.","date":"1994","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7509720","citation_count":163,"is_preprint":false},{"pmid":"9298694","id":"PMC_9298694","title":"CD44 in inflammation and metastasis.","date":"1997","source":"Glycoconjugate journal","url":"https://pubmed.ncbi.nlm.nih.gov/9298694","citation_count":162,"is_preprint":false},{"pmid":"10449175","id":"PMC_10449175","title":"Activation and interaction of CD44 and hyaluronan in immunological systems.","date":"1999","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/10449175","citation_count":161,"is_preprint":false},{"pmid":"8601595","id":"PMC_8601595","title":"Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan.","date":"1996","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8601595","citation_count":158,"is_preprint":false},{"pmid":"28986884","id":"PMC_28986884","title":"The Role of CD44 and Cancer Stem Cells.","date":"2018","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/28986884","citation_count":156,"is_preprint":false},{"pmid":"18490190","id":"PMC_18490190","title":"Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance.","date":"2008","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/18490190","citation_count":153,"is_preprint":false},{"pmid":"1688719","id":"PMC_1688719","title":"Hematopoietic progenitor cell expression of the H-CAM (CD44) homing-associated adhesion molecule.","date":"1990","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/1688719","citation_count":152,"is_preprint":false},{"pmid":"9231152","id":"PMC_9231152","title":"CD44 and the adhesion of neoplastic cells.","date":"1997","source":"Molecular pathology : MP","url":"https://pubmed.ncbi.nlm.nih.gov/9231152","citation_count":151,"is_preprint":false},{"pmid":"20079666","id":"PMC_20079666","title":"CD44 regulates survival and memory development in Th1 cells.","date":"2010","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/20079666","citation_count":149,"is_preprint":false},{"pmid":"1922057","id":"PMC_1922057","title":"Expression of CD44 is repressed in neuroblastoma cells.","date":"1991","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1922057","citation_count":146,"is_preprint":false},{"pmid":"25999819","id":"PMC_25999819","title":"CD44: molecular interactions, signaling and functions in the nervous system.","date":"2015","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25999819","citation_count":140,"is_preprint":false},{"pmid":"29519253","id":"PMC_29519253","title":"The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor.","date":"2018","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/29519253","citation_count":138,"is_preprint":false},{"pmid":"35431911","id":"PMC_35431911","title":"CD44-Targeted Nanocarrier for Cancer Therapy.","date":"2022","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35431911","citation_count":135,"is_preprint":false},{"pmid":"25301071","id":"PMC_25301071","title":"CD44 functions in Wnt signaling by regulating LRP6 localization and activation.","date":"2014","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/25301071","citation_count":135,"is_preprint":false},{"pmid":"9611772","id":"PMC_9611772","title":"The CD44 protein family.","date":"1998","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9611772","citation_count":124,"is_preprint":false},{"pmid":"27578526","id":"PMC_27578526","title":"The role of CD44 in glioblastoma multiforme.","date":"2016","source":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","url":"https://pubmed.ncbi.nlm.nih.gov/27578526","citation_count":120,"is_preprint":false},{"pmid":"14623895","id":"PMC_14623895","title":"Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14623895","citation_count":120,"is_preprint":false},{"pmid":"16455948","id":"PMC_16455948","title":"CD44 is a phagocytic receptor.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16455948","citation_count":117,"is_preprint":false},{"pmid":"15480059","id":"PMC_15480059","title":"Hyaluronan and CD44: modulators of chondrocyte metabolism.","date":"2004","source":"Clinical orthopaedics and related research","url":"https://pubmed.ncbi.nlm.nih.gov/15480059","citation_count":113,"is_preprint":false},{"pmid":"9634544","id":"PMC_9634544","title":"CD44 structure and function.","date":"1998","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/9634544","citation_count":109,"is_preprint":false},{"pmid":"22549467","id":"PMC_22549467","title":"Regulation of ABCB1/PGP1-catalysed auxin transport by linker phosphorylation.","date":"2012","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/22549467","citation_count":108,"is_preprint":false},{"pmid":"25741341","id":"PMC_25741341","title":"Interactions between CD44 and Hyaluronan in Leukocyte Trafficking.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25741341","citation_count":107,"is_preprint":false},{"pmid":"7535522","id":"PMC_7535522","title":"CD44 isoforms during differentiation and development.","date":"1995","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/7535522","citation_count":107,"is_preprint":false},{"pmid":"12741678","id":"PMC_12741678","title":"CD44 and its partners in metastasis.","date":"2003","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/12741678","citation_count":98,"is_preprint":false},{"pmid":"32830349","id":"PMC_32830349","title":"The role of CD44 in pathological angiogenesis.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32830349","citation_count":95,"is_preprint":false},{"pmid":"12723975","id":"PMC_12723975","title":"CD44 in rheumatoid arthritis.","date":"2003","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/12723975","citation_count":92,"is_preprint":false},{"pmid":"25472903","id":"PMC_25472903","title":"Perspectives of CD44 targeting therapies.","date":"2014","source":"Archives of toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/25472903","citation_count":90,"is_preprint":false},{"pmid":"22758394","id":"PMC_22758394","title":"Role of CD44 in tumour progression and strategies for targeting.","date":"2012","source":"Journal of drug targeting","url":"https://pubmed.ncbi.nlm.nih.gov/22758394","citation_count":90,"is_preprint":false},{"pmid":"22457624","id":"PMC_22457624","title":"Peptidoglycan-modifying enzyme Pgp1 is required for helical cell shape and pathogenicity traits in Campylobacter jejuni.","date":"2012","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/22457624","citation_count":86,"is_preprint":false},{"pmid":"26261555","id":"PMC_26261555","title":"Expression of CD44 in pancreatic cancer and its significance.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26261555","citation_count":84,"is_preprint":false},{"pmid":"7545465","id":"PMC_7545465","title":"CD44 (Pgp-1) inhibits CD3 and dexamethasone-induced apoptosis.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7545465","citation_count":84,"is_preprint":false},{"pmid":"31839599","id":"PMC_31839599","title":"Role of CD44 in breast cancer.","date":"2020","source":"Breast disease","url":"https://pubmed.ncbi.nlm.nih.gov/31839599","citation_count":83,"is_preprint":false},{"pmid":"8505366","id":"PMC_8505366","title":"CD44 expression on murine tissues.","date":"1993","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/8505366","citation_count":82,"is_preprint":false},{"pmid":"33961871","id":"PMC_33961871","title":"The role of CD44 in cancer chemoresistance: A concise review.","date":"2021","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33961871","citation_count":81,"is_preprint":false},{"pmid":"22726066","id":"PMC_22726066","title":"CD44 in human glioma correlates with histopathological grade and cell migration.","date":"2012","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/22726066","citation_count":79,"is_preprint":false},{"pmid":"18322236","id":"PMC_18322236","title":"CD44 suppresses TLR-mediated inflammation.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18322236","citation_count":78,"is_preprint":false},{"pmid":"25566991","id":"PMC_25566991","title":"CD44 regulates pancreatic cancer invasion through MT1-MMP.","date":"2015","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/25566991","citation_count":77,"is_preprint":false},{"pmid":"34513617","id":"PMC_34513617","title":"Understanding Hyaluronan Receptor (CD44) Interaction, HA-CD44 Activated Potential Targets in Cancer Therapeutics.","date":"2020","source":"Advanced pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/34513617","citation_count":75,"is_preprint":false},{"pmid":"17092433","id":"PMC_17092433","title":"CD44 and hematologic malignancies.","date":"2006","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17092433","citation_count":73,"is_preprint":false},{"pmid":"31593802","id":"PMC_31593802","title":"CD44(+) tumor cells promote early angiogenesis in head and neck squamous cell carcinoma.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/31593802","citation_count":72,"is_preprint":false},{"pmid":"19174187","id":"PMC_19174187","title":"Rheostatic signaling by CD44 and hyaluronan.","date":"2009","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/19174187","citation_count":69,"is_preprint":false},{"pmid":"7577002","id":"PMC_7577002","title":"CD44 in colon cancer.","date":"1995","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/7577002","citation_count":69,"is_preprint":false},{"pmid":"30130585","id":"PMC_30130585","title":"Hyaluronic acid, CD44 and RHAMM regulate myoblast behavior during embryogenesis.","date":"2018","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30130585","citation_count":65,"is_preprint":false},{"pmid":"10609783","id":"PMC_10609783","title":"Signal transduction via CD44: role of plasma membrane microdomains.","date":"1999","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/10609783","citation_count":62,"is_preprint":false},{"pmid":"16580085","id":"PMC_16580085","title":"Expression of CD44 in rat hepatic progenitor cells.","date":"2006","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/16580085","citation_count":61,"is_preprint":false},{"pmid":"21258793","id":"PMC_21258793","title":"CD44 in hematological neoplasias.","date":"2011","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/21258793","citation_count":60,"is_preprint":false},{"pmid":"25081531","id":"PMC_25081531","title":"HAS2 and CD44 in breast tumorigenesis.","date":"2014","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25081531","citation_count":57,"is_preprint":false},{"pmid":"25101858","id":"PMC_25101858","title":"CD44 acts through RhoA to regulate YAP signaling.","date":"2014","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25101858","citation_count":57,"is_preprint":false},{"pmid":"17911438","id":"PMC_17911438","title":"CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice.","date":"2007","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17911438","citation_count":54,"is_preprint":false},{"pmid":"31654718","id":"PMC_31654718","title":"Involvement of hyaluronan and CD44 in cancer and viral infections.","date":"2019","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/31654718","citation_count":52,"is_preprint":false},{"pmid":"21471434","id":"PMC_21471434","title":"CD44-SLC1A2 gene fusions in gastric cancer.","date":"2011","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21471434","citation_count":52,"is_preprint":false},{"pmid":"11754374","id":"PMC_11754374","title":"CD44 expression in human gliomas.","date":"2002","source":"Journal of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11754374","citation_count":51,"is_preprint":false},{"pmid":"18661347","id":"PMC_18661347","title":"Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer.","date":"2008","source":"Connective tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/18661347","citation_count":50,"is_preprint":false},{"pmid":"28523716","id":"PMC_28523716","title":"CD44+ fibroblasts increases breast cancer cell survival and drug resistance via IGF2BP3-CD44-IGF2 signalling.","date":"2017","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28523716","citation_count":50,"is_preprint":false},{"pmid":"7544777","id":"PMC_7544777","title":"CD44 isoforms in metastatic cancer.","date":"1994","source":"Invasion & metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/7544777","citation_count":49,"is_preprint":false},{"pmid":"14580646","id":"PMC_14580646","title":"The hyaluronic acid receptor (CD44) is expressed in bovine oocytes and early stage embryos.","date":"2003","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/14580646","citation_count":49,"is_preprint":false},{"pmid":"29983670","id":"PMC_29983670","title":"CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications.","date":"2018","source":"Clinical proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/29983670","citation_count":48,"is_preprint":false},{"pmid":"12534600","id":"PMC_12534600","title":"Hyaluronan, CD44 and versican in epidermal keratinocyte tumours.","date":"2003","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/12534600","citation_count":47,"is_preprint":false},{"pmid":"30288117","id":"PMC_30288117","title":"CD44 is overexpressed and correlated with tumor progression in gallbladder cancer.","date":"2018","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/30288117","citation_count":46,"is_preprint":false},{"pmid":"25870596","id":"PMC_25870596","title":"Modulation of CD44 Activity by A6-Peptide.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25870596","citation_count":45,"is_preprint":false},{"pmid":"9172805","id":"PMC_9172805","title":"CD44 and hyaluronan binding by human myeloid cells.","date":"1996","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/9172805","citation_count":45,"is_preprint":false},{"pmid":"23208496","id":"PMC_23208496","title":"CD44 promotes Kras-dependent lung adenocarcinoma.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23208496","citation_count":45,"is_preprint":false},{"pmid":"1671863","id":"PMC_1671863","title":"Full length and alternatively spliced pgp1 transcripts in multidrug-resistant Chinese hamster lung cells.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1671863","citation_count":44,"is_preprint":false},{"pmid":"31516234","id":"PMC_31516234","title":"Structure, function and role of CD44 in neoplasia.","date":"2019","source":"Journal of oral and maxillofacial pathology : JOMFP","url":"https://pubmed.ncbi.nlm.nih.gov/31516234","citation_count":43,"is_preprint":false},{"pmid":"26569327","id":"PMC_26569327","title":"Expression and Function of CD44 in Epithelial Ovarian Carcinoma.","date":"2015","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/26569327","citation_count":43,"is_preprint":false},{"pmid":"11840384","id":"PMC_11840384","title":"CD44 expression in IgA nephropathy.","date":"2002","source":"American journal of kidney diseases : the official journal of the National Kidney Foundation","url":"https://pubmed.ncbi.nlm.nih.gov/11840384","citation_count":41,"is_preprint":false},{"pmid":"37835592","id":"PMC_37835592","title":"A Narrative Review on CD44's Role in Glioblastoma Invasion, Proliferation, and Tumor Recurrence.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37835592","citation_count":40,"is_preprint":false},{"pmid":"10541973","id":"PMC_10541973","title":"Expression of CD44 variants in osteosarcoma.","date":"1999","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/10541973","citation_count":40,"is_preprint":false},{"pmid":"12168806","id":"PMC_12168806","title":"CD44: functional relevance to inflammation and malignancy.","date":"2002","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/12168806","citation_count":40,"is_preprint":false},{"pmid":"28715483","id":"PMC_28715483","title":"Atomistic fingerprint of hyaluronan-CD44 binding.","date":"2017","source":"PLoS computational biology","url":"https://pubmed.ncbi.nlm.nih.gov/28715483","citation_count":39,"is_preprint":false},{"pmid":"34087104","id":"PMC_34087104","title":"The CD44/COL17A1 pathway promotes the formation of multilayered, transformed epithelia.","date":"2021","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/34087104","citation_count":38,"is_preprint":false},{"pmid":"33911148","id":"PMC_33911148","title":"MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33911148","citation_count":34,"is_preprint":false},{"pmid":"21117172","id":"PMC_21117172","title":"Proteomic identification of CD44 interacting proteins.","date":"2010","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/21117172","citation_count":34,"is_preprint":false},{"pmid":"33687952","id":"PMC_33687952","title":"Androgen Receptor Regulates CD44 Expression in Bladder Cancer.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33687952","citation_count":33,"is_preprint":false},{"pmid":"24850301","id":"PMC_24850301","title":"CD44 clustering is involved in monocyte differentiation.","date":"2014","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/24850301","citation_count":32,"is_preprint":false},{"pmid":"38783892","id":"PMC_38783892","title":"CD44 and its implication in neoplastic diseases.","date":"2024","source":"MedComm","url":"https://pubmed.ncbi.nlm.nih.gov/38783892","citation_count":31,"is_preprint":false},{"pmid":"25204555","id":"PMC_25204555","title":"PTK7 regulates Id1 expression in CD44-high glioma cells.","date":"2014","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25204555","citation_count":31,"is_preprint":false},{"pmid":"22887934","id":"PMC_22887934","title":"CD44(+) cells have cancer stem cell-like properties in nasopharyngeal carcinoma.","date":"2012","source":"International forum of allergy & rhinology","url":"https://pubmed.ncbi.nlm.nih.gov/22887934","citation_count":31,"is_preprint":false},{"pmid":"29218080","id":"PMC_29218080","title":"Whether CD44 is an applicable marker for glioma stem cells.","date":"2017","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/29218080","citation_count":31,"is_preprint":false},{"pmid":"30089233","id":"PMC_30089233","title":"The role of CD44, hyaluronan and NHE1 in cardiac remodeling.","date":"2018","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30089233","citation_count":30,"is_preprint":false},{"pmid":"35954411","id":"PMC_35954411","title":"CD44 Depletion in Glioblastoma Cells Suppresses Growth and Stemness and Induces Senescence.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35954411","citation_count":30,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43389,"output_tokens":5591,"usd":0.107016,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14267,"output_tokens":5467,"usd":0.104005,"stage2_stop_reason":"end_turn"},"total_usd":0.211021,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"CD44 mediates the endocytosis and lysosomal degradation of hyaluronan; antibodies against CD44 block HA uptake and internalization in fibroblasts and macrophages, and agents blocking lysosomal acidification (chloroquine, NH4Cl) inhibit subsequent HA degradation. CD44 itself lacks intrinsic degradative activity, as isolated membrane preparations containing CD44 do not break down HA.\",\n      \"method\": \"Isotopic labeling of hyaluronan, molecular-sieve chromatography, antibody blocking, fluorescein-tagged HA internalization assay, lysosomal inhibitors\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (radiolabeled substrate degradation assay, fluorescent internalization, antibody blocking, pharmacological inhibition) in two cell types; replicated internally with rigorous controls\",\n      \"pmids\": [\"1370836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"N-linked glycosylation of CD44 is required for hyaluronan binding; tunicamycin abolishes HA-mediated cell adhesion, while mutation of any one of five N-linked glycosylation sites within the HA-recognition domain abrogates binding. Mutation of Ser-Gly motifs providing glycosaminoglycan attachment sites in the membrane-proximal domain also impairs HA binding, indicating that specific glycosylation patterns maintain the HA-recognition domain in the appropriate conformation.\",\n      \"method\": \"Tunicamycin treatment, deoxymannojirimycin treatment, site-directed mutagenesis of N-linked glycosylation sites, stable transfection of CD44 mutants, cell adhesion assay on HA-coated substrate\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic mutagenesis of all five glycosylation sites combined with pharmacological inhibitors and functional adhesion readout in stably transfected cells\",\n      \"pmids\": [\"8601595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"HA binding at the cell surface involves multivalent interactions dependent on HA size, CD44 density, and CD44 activation state. Monovalent binding requires 6–18 sugar residues; divalent binding begins at ~20–38 residues. An inducing anti-CD44 mAb (IRAWB14) dramatically slows HA dissociation from the cell surface (without affecting binding kinetics), revealing that CD44 activation state is a key regulator of HA retention.\",\n      \"method\": \"Competitive inhibition assay with fluorescein-conjugated HA, defined-size HA oligomers, kinetic binding/dissociation studies, monoclonal antibody activation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — quantitative binding assay with defined oligomer sizes and kinetic measurements, multiple orthogonal approaches in one study\",\n      \"pmids\": [\"10871609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CD44 undergoes ectodomain shedding catalyzed by ADAM10 (a disintegrin and metalloproteinase 10), which is augmented by CD44 ligation and Rac1-mediated cytoskeletal rearrangement. CD44 engagement activates Rac1, causing redistribution of CD44 to membrane ruffles at the leading edge; ADAM10 knockdown by RNAi suppresses CD44 cleavage. CD44 cleavage promotes tumor cell migration and invasion.\",\n      \"method\": \"Metalloproteinase inhibitors (KB-R7785, TIMP-1, TIMP-2), RNA interference of ADAM10, FRET-based visualization of active Rac1 in living cells, cell morphology/actin cytoskeleton analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — RNAi-based identification of ADAM10, FRET-based live-cell Rac1 activation, pharmacological inhibitors with functional migration readout; multiple orthogonal methods\",\n      \"pmids\": [\"14623895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CD44 undergoes sequential proteolytic cleavages: (1) ectodomain shedding regulated by metalloproteinases and triggered by multiple stimuli, which controls cell attachment to and migration on HA matrix; (2) subsequent intramembranous cleavage by presenilin-dependent γ-secretase, generating a CD44 intracellular domain (CD44-ICD) that translocates to the nucleus and activates transcription.\",\n      \"method\": \"Biochemical analysis of cleavage fragments, γ-secretase inhibition, nuclear translocation assays\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — review synthesizing experimental findings from multiple laboratories; mechanistic details (γ-secretase, nuclear translocation) are cited from experimental studies but abstract-level detail is limited\",\n      \"pmids\": [\"15596040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CD44 functions as a primary phagocytic receptor: macrophages expressing CD44 efficiently engulf HA-coated beads and anti-CD44-opsonized erythrocytes via a mechanism involving Syk kinase, Rac1, and PI3-kinase, and inducing phagocyte oxidase activation. CD44-deficient macrophages cannot perform this phagocytosis, and the pathway is independent of Fc receptors.\",\n      \"method\": \"Hyaluronan-coated beads, anti-CD44-opsonized erythrocyte engulfment, CD44 knockout macrophages, immunoprecipitation, pharmacological inhibition (Syk, PI3K), genetic deletion\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout macrophages, pharmacological inhibitors, and multiple substrates used together; clear primary receptor function demonstrated with rigorous controls\",\n      \"pmids\": [\"16455948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CD44 directly associates with TLR2 upon stimulation by the TLR2 ligand zymosan and negatively regulates TLR-mediated NF-κB activation and proinflammatory cytokine production in vivo. The cytoplasmic domain of CD44 is required for this regulatory effect on TLR signaling.\",\n      \"method\": \"Co-immunoprecipitation of CD44 and TLR2, cytoplasmic domain deletion constructs, in vivo inflammation models, cytokine measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct association shown by co-IP, domain requirement demonstrated by cytoplasmic deletion, but single-lab study\",\n      \"pmids\": [\"18322236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CD44 promotes survival of effector Th1 cells by limiting Fas-mediated apoptosis, thereby enabling memory Th1 cell generation. CD44 ligation engages the PI3K-Akt signaling pathway in Th1 cells. This survival function is Th1-specific and is not observed in Th2, Th17, or CD8+ T cells despite equivalent CD44 expression.\",\n      \"method\": \"CD44-deficient mice, Th1/Th2/Th17/CD8+ T cell subset analysis, apoptosis assays, PI3K-Akt signaling pathway measurement\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with precise subset-specific phenotype, signaling pathway identified, replicated across multiple T cell subsets as internal controls\",\n      \"pmids\": [\"20079666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CD44 interacts with IQGAP1 (an actin-binding protein) via its intracellular C-terminus; an endogenous CD44-IQGAP1 complex was demonstrated in normal and transformed cell types, linking CD44 to cytoskeletal reorganization.\",\n      \"method\": \"Peptide-based pull-down with phosphorylated/non-phosphorylated CD44 C-terminal peptides, MALDI-TOF mass spectrometry identification, co-immunoprecipitation of endogenous complex\",\n      \"journal\": \"IUBMB life\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pull-down identified partners; endogenous complex confirmed by Co-IP in multiple cell types; single lab but two orthogonal methods\",\n      \"pmids\": [\"21117172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CD44 acts as a positive regulator of the Wnt receptor complex by physically associating with LRP6 upon Wnt stimulation and modulating LRP6 membrane localization. CD44 knockdown decreases, and overexpression increases, Wnt/β-catenin signaling activity. Epistasis experiments place CD44 function at the level of LRP6. CD44 regulates Wnt target gene expression (tcf-4 and en-2) in Xenopus brain development.\",\n      \"method\": \"Co-immunoprecipitation of CD44 and LRP6, CD44 knockdown/overexpression, Wnt reporter assay, epistasis analysis, CD44 morpholino knockdown in Xenopus laevis embryos\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, genetic epistasis, in vivo Xenopus morphant validation, and dose-dependent reporter assays provide multiple orthogonal lines of evidence\",\n      \"pmids\": [\"25301071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CD44 signals through RhoA to regulate YAP expression and nuclear localization in the Hippo pathway. CD44 knockdown reduces RhoA expression, and constitutively active RhoA (RhoA-V14) rescues the YAP decrease caused by CD44 knockdown. CD44 knockdown also reduces expression of YAP target genes (CTGF, Cyr61, EDN1) and promotes apoptosis while inhibiting proliferation and migration.\",\n      \"method\": \"RNAi knockdown of CD44, overexpression of constitutively active RhoA, qRT-PCR of YAP targets, cell proliferation/apoptosis/migration assays\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis by rescue with constitutively active RhoA, consistent phenotypic readouts; single lab\",\n      \"pmids\": [\"25101858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CD44 regulates pancreatic cancer invasion through a CD44→Snail1→MT1-MMP (MMP14) axis: CD44 drives expression of the EMT transcription factor Snail1, which in turn regulates membrane-bound MT1-MMP expression required for invasion. Loss of CD44 reduces Snail1 and MT1-MMP levels and abolishes invasion in vitro and in vivo.\",\n      \"method\": \"CD44 knockdown/overexpression in pancreatic cancer cells, western blot for Snail1 and MT1-MMP, invasion assays, in vivo tumor models\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined signaling axis with multiple molecular readouts and in vivo confirmation; single lab\",\n      \"pmids\": [\"25566991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Atomistic molecular dynamics simulations reveal that hyaluronan binds CD44's hyaluronan-binding domain via three topographically distinct binding modes. The crystallographic mode is the strongest; two metastable modes are more frequently observed in unbiased simulations. CD44 can diffuse along HA in a 1D manner when attached via weaker modes, potentially influencing CD44 aggregation kinetics relevant to signaling.\",\n      \"method\": \"Atomistic molecular dynamics simulations with multiple independent runs, comparison to X-ray crystallographic binding mode\",\n      \"journal\": \"PLoS computational biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Moderate — computational/simulation only, no direct experimental validation of the two new binding modes; replicated within computational framework\",\n      \"pmids\": [\"28715483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GPNMB attenuates astrocyte inflammatory responses through CD44: recombinant GPNMB reduces cytokine-induced iNOS, nitric oxide, ROS, and IL-6 in astrocytes, and this anti-inflammatory effect is abolished in CD44 knockout astrocytes, establishing CD44 as the required receptor for GPNMB-mediated neuroprotection.\",\n      \"method\": \"Recombinant GPNMB treatment, CD44 knockout primary astrocytes, qPCR, nitric oxide and ROS measurement, immunofluorescence\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CD44 KO used to confirm receptor requirement; multiple inflammatory markers measured; single lab\",\n      \"pmids\": [\"29519253\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CD44 mediates endocytosis of iron-bound hyaluronates, providing an alternative iron-uptake mechanism in mesenchymal-state cells. Internalized iron acts as a metal catalyst to demethylate repressive histone marks (H3K9me2/me3 and H3K27me3), thereby governing expression of mesenchymal genes and enabling epigenetic plasticity. CD44 expression is itself transcriptionally upregulated by nuclear iron through a positive feedback loop, in contrast to the negative iron regulation of transferrin receptor.\",\n      \"method\": \"Iron-bound hyaluronate endocytosis assays in tumorigenic cell lines and primary cancer cells, histone methylation profiling, small-molecule interference with iron homeostasis, EMT induction assays\",\n      \"journal\": \"Nature chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic pathway from CD44 endocytosis to epigenetic modification demonstrated with multiple orthogonal approaches (endocytosis assays, histone marks, gene expression, primary cancer cells and tumors), single lab with rigorous methods\",\n      \"pmids\": [\"32747755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CD44 regulates membrane accumulation of COL17A1 (collagen XVII) in multilayered transformed epithelia. CD44 and COL17A1 accumulate in oncogene (RasV12, Src, ErbB2)-transformed epithelial cells, suppress mitochondrial ROS production, and thereby promote resistance to ferroptosis-mediated cell death during cell extrusion, enabling clonal expansion of transformed cells.\",\n      \"method\": \"Plasma membrane protein screening, COL17A1 knockout in RasV12 cells, metabolome analysis, ROS and mitochondrial membrane potential measurement, in vitro and in vivo multilayered epithelial models\",\n      \"journal\": \"Current biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CD44's specific role in COL17A1 membrane accumulation defined, linked to ROS/ferroptosis resistance by KO and metabolomics; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"34087104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CD44 is required for Kras-mediated MAPK signaling and lung adenocarcinoma formation in vivo: deletion of CD44 in a KrasG12D mouse model attenuates MAPK pathway activation, reduces tumor cell proliferation, decreases lung adenocarcinoma formation, and prolongs survival.\",\n      \"method\": \"Cre-mediated KrasG12D lung cancer mouse model with CD44 deletion, MAPK signaling assays, tumor burden quantification, survival analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic epistasis placing CD44 upstream of MAPK in Kras-driven cancer; single lab\",\n      \"pmids\": [\"23208496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CD44 engagement (by HA or anti-CD44 mAbs) inhibits apoptosis induced by anti-CD3 mAbs and dexamethasone in T cells, but not UV-induced (p53-dependent) apoptosis, without upregulating Bcl-2 or affecting proliferation. This places CD44 as a survival signal that specifically counteracts TCR- and glucocorticoid-mediated apoptotic pathways.\",\n      \"method\": \"Anti-CD44 antibody and HA ligation, DNA fragmentation assay, apoptosis quantification, Bcl-2 expression analysis in 3DO T-cell line\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific pathway positioning (anti-CD3/dexamethasone vs. UV/p53) with multiple stimuli and Bcl-2 exclusion; single lab\",\n      \"pmids\": [\"7545465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CD44 depletion (CRISPR/Cas9 KO) in GBM cells impairs proliferation (decreased Ki67, reduced CREB phosphorylation, elevated p16), decreases stemness, and induces senescence. γ-Secretase inhibition (DAPT, blocking CD44-ICD release) phenocopies some of these effects, suggesting CD44-ICD-dependent transcriptional regulation. CD44 KO also deregulates HAS2 and hyaluronan synthesis, and downregulation of HAS2 reduces CD44 protein levels, indicating a CD44/hyaluronan positive feedback circuit.\",\n      \"method\": \"CRISPR/Cas9 CD44 knockout, γ-secretase inhibitor DAPT, RNA sequencing, Ki67 staining, p16/CREB phosphorylation western blot, sphere formation assays\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with RNA-seq and multiple molecular readouts; γ-secretase inhibitor confirms ICD-dependent transcription; single lab\",\n      \"pmids\": [\"35954411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Androgen receptor (AR) directly represses CD44 transcription through a novel androgen response element silencer in the CD44 locus, as demonstrated by CRISPR-based mutagenesis of the ARE. AR ChIP-seq and transcriptomics confirmed CD44 as an AR-regulated gene, and AR and CD44 expression are inversely correlated in human bladder tumors.\",\n      \"method\": \"AR ChIP sequencing, transcriptomics, CRISPR mutagenesis of androgen response elements, pooled shRNA/ORF functional genomics screens, human tumor expression correlation\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — CRISPR ARE mutagenesis directly establishes causal silencer element; supported by ChIP-seq and transcriptomics; single lab with multiple rigorous approaches\",\n      \"pmids\": [\"33687952\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD44 is a transmembrane glycoprotein that functions as the primary cell surface receptor for hyaluronan, mediating HA endocytosis and lysosomal degradation, and whose HA-binding capacity is regulated by cell-type-specific N-linked and O-linked glycosylation; CD44 undergoes sequential ectodomain shedding (by ADAM10, augmented by Rac1-mediated cytoskeletal rearrangement) and intramembranous γ-secretase cleavage releasing a nuclear ICD that activates transcription; it acts as a co-receptor for LRP6 in Wnt signaling, associates with TLR2 to suppress NF-κB-mediated inflammation, signals through RhoA to regulate YAP/Hippo output, promotes Th1 cell survival via PI3K-Akt/Fas pathway suppression, drives pancreatic cancer invasion through a Snail1→MT1-MMP axis, supports Kras-MAPK signaling in lung adenocarcinoma, mediates phagocytosis via Syk/Rac1/PI3K, and orchestrates iron endocytosis via iron-bound hyaluronates to catalyze histone demethylation and epigenetic plasticity in mesenchymal-state cancer cells.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CD44 is a transmembrane glycoprotein that serves as the principal cell-surface receptor for hyaluronan (HA), mediating HA endocytosis and routing it to lysosomes for degradation, although the protein itself has no intrinsic catalytic activity toward HA [#0]. HA recognition is conformationally gated by glycosylation: N-linked glycans at multiple sites within the HA-recognition domain, together with membrane-proximal glycosaminoglycan attachment motifs, are required for binding, and the avidity of the interaction scales with HA size, receptor density, and an inducible activation state that controls ligand retention [#1, #2]. CD44 transduces these adhesive cues into intracellular signaling and is regulated by sequential proteolysis: ADAM10-catalyzed ectodomain shedding, augmented by CD44 ligation and Rac1-driven cytoskeletal remodeling, is followed by γ-secretase intramembrane cleavage to liberate a CD44 intracellular domain (CD44-ICD) that enters the nucleus and activates transcription [#3, #4]. Through its cytoplasmic tail CD44 couples to cytoskeletal and signaling machinery—binding IQGAP1, signaling via RhoA to sustain YAP/Hippo output, and engaging Syk/Rac1/PI3K to act as a phagocytic receptor independent of Fc receptors [#5, #8, #10]. CD44 functions as a Wnt co-receptor by associating with and positioning LRP6 [#9], suppresses TLR2-driven NF-κB inflammation via its cytoplasmic domain [#6], and promotes lymphocyte survival by engaging PI3K-Akt to limit Fas-mediated apoptosis [#7, #17]. In cancer, CD44 supports Kras-MAPK-driven lung adenocarcinoma, drives invasion through a Snail1→MT1-MMP axis, sustains stemness and proliferation through CD44-ICD-dependent transcription, and orchestrates endocytosis of iron-bound hyaluronates that catalyzes histone demethylation to enforce mesenchymal epigenetic plasticity through an iron-CD44 positive feedback loop [#11, #14, #16, #18]. CD44 itself is transcriptionally repressed by the androgen receptor through a defined androgen-response-element silencer [#19].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Established CD44's core physiological function—whether the HA receptor merely binds HA or actively clears it—by showing it drives HA internalization and lysosomal degradation without itself being catalytic.\",\n      \"evidence\": \"Radiolabeled and fluorescent HA uptake/degradation assays with antibody blocking and lysosomal inhibitors in fibroblasts and macrophages\",\n      \"pmids\": [\"1370836\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the molecular determinants of HA binding affinity\", \"Mechanism coupling surface binding to internalization not resolved\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Resolved why HA-binding capacity varies between cell types by demonstrating that N-linked glycosylation and GAG-attachment motifs maintain the HA-recognition domain in a binding-competent conformation.\",\n      \"evidence\": \"Tunicamycin treatment plus systematic site-directed mutagenesis of glycosylation sites with HA-adhesion readout in transfectants\",\n      \"pmids\": [\"8601595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the conformational requirement not directly determined\", \"Cell-type-specific glycosylation enzymes not identified\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Quantified how CD44 retains HA by showing multivalent, size-dependent binding and an inducible activation state that slows ligand dissociation, distinguishing avidity control from affinity.\",\n      \"evidence\": \"Competitive binding with defined HA oligomers and kinetic dissociation studies, plus activating mAb\",\n      \"pmids\": [\"10871609\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular nature of the activation state not defined\", \"In vivo relevance of multivalency not established\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified the protease and cytoskeletal trigger for CD44 ectodomain release, linking receptor ligation to ADAM10-dependent shedding and tumor cell migration.\",\n      \"evidence\": \"ADAM10 RNAi, metalloproteinase inhibitors, and FRET imaging of Rac1 activation with migration assays\",\n      \"pmids\": [\"14623895\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address downstream fate of the shed ectodomain or the membrane-retained stub\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Placed shedding in a regulated intramembrane proteolysis sequence, establishing that γ-secretase releases a transcriptionally active CD44-ICD after ectodomain cleavage.\",\n      \"evidence\": \"Biochemical cleavage analysis, γ-secretase inhibition, and nuclear translocation assays (review-level synthesis)\",\n      \"pmids\": [\"15596040\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets of CD44-ICD not enumerated here\", \"Review-level detail; primary mechanistic data limited\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated CD44 acts as a bona fide phagocytic receptor, defining a Syk/Rac1/PI3K signaling route distinct from Fc-receptor phagocytosis.\",\n      \"evidence\": \"HA-bead and anti-CD44-opsonized erythrocyte engulfment in CD44-knockout macrophages with Syk/PI3K inhibitors\",\n      \"pmids\": [\"16455948\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical link between CD44 tail and Syk recruitment not shown\", \"Physiological clearance targets in vivo not defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Revealed an immunoregulatory function by showing CD44 physically associates with TLR2 and dampens NF-κB-driven inflammation through its cytoplasmic domain.\",\n      \"evidence\": \"Co-IP of CD44/TLR2, cytoplasmic-domain deletion constructs, and in vivo cytokine measurement\",\n      \"pmids\": [\"18322236\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study without reciprocal validation across systems\", \"Cytoplasmic effector mediating NF-κB suppression unidentified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined a subset-specific survival role, showing CD44 engages PI3K-Akt to limit Fas-mediated apoptosis and enable Th1 memory generation.\",\n      \"evidence\": \"CD44-deficient mice with Th1/Th2/Th17/CD8 subset comparison and apoptosis/PI3K-Akt readouts\",\n      \"pmids\": [\"20079666\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why the survival function is Th1-restricted despite equal expression unexplained\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected CD44's cytoplasmic tail to the actin cytoskeleton by identifying an endogenous CD44-IQGAP1 complex.\",\n      \"evidence\": \"Phospho/non-phospho C-terminal peptide pull-down with MS identification and Co-IP of endogenous complex\",\n      \"pmids\": [\"21117172\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of the interaction not tested\", \"Phosphorylation dependence not resolved functionally\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established CD44 as a Wnt pathway co-receptor acting at the level of LRP6 to tune β-catenin signaling.\",\n      \"evidence\": \"Reciprocal Co-IP, knockdown/overexpression reporter assays, epistasis, and Xenopus morphant validation\",\n      \"pmids\": [\"25301071\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which CD44 controls LRP6 membrane localization not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linked CD44 to Hippo output by showing it signals through RhoA to maintain YAP expression and nuclear localization.\",\n      \"evidence\": \"CD44 RNAi with constitutively active RhoA rescue and YAP-target qRT-PCR plus phenotypic assays\",\n      \"pmids\": [\"25101858\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How CD44 activates RhoA not established\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Provided in vivo genetic evidence that CD44 is required for Kras-MAPK signaling and lung adenocarcinoma formation.\",\n      \"evidence\": \"CD44 deletion in a KrasG12D lung cancer mouse model with MAPK, tumor burden, and survival analysis\",\n      \"pmids\": [\"23208496\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Biochemical step linking CD44 to MAPK activation undefined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined a pro-invasive signaling axis, placing CD44 upstream of Snail1-driven MT1-MMP expression in pancreatic cancer.\",\n      \"evidence\": \"CD44 knockdown/overexpression with Snail1/MT1-MMP western blots, invasion assays, and in vivo tumor models\",\n      \"pmids\": [\"25566991\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which CD44 induces Snail1 not defined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Positioned CD44 as a selective anti-apoptotic signal that counteracts TCR- and glucocorticoid-induced but not p53-dependent death.\",\n      \"evidence\": \"Anti-CD44/HA ligation with DNA fragmentation and Bcl-2 analysis in a T-cell line\",\n      \"pmids\": [\"7545465\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream survival effector not identified (Bcl-2 excluded)\", \"Single cell-line system\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified CD44 as the required receptor for GPNMB-mediated anti-inflammatory neuroprotection in astrocytes.\",\n      \"evidence\": \"Recombinant GPNMB on CD44-knockout primary astrocytes with iNOS/NO/ROS/IL-6 readouts\",\n      \"pmids\": [\"29519253\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct CD44-GPNMB binding not demonstrated\", \"Downstream signaling not mapped\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Uncovered a non-canonical role linking CD44 endocytosis to the epigenome, showing iron-bound HA uptake catalyzes histone demethylation and drives mesenchymal plasticity through an iron-CD44 feedback loop.\",\n      \"evidence\": \"Iron-HA endocytosis assays, histone methylation profiling, iron-homeostasis perturbation, and EMT assays in cancer cells and tumors\",\n      \"pmids\": [\"32747755\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific demethylases catalyzing the marks not identified\", \"Mechanism of nuclear iron delivery from endosome unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Tied CD44-ICD transcriptional output to glioblastoma stemness and senescence escape, and linked CD44 to a HAS2/hyaluronan feedback circuit.\",\n      \"evidence\": \"CRISPR CD44 knockout with RNA-seq, DAPT γ-secretase inhibition, and proliferation/stemness/senescence assays\",\n      \"pmids\": [\"35954411\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct CD44-ICD target genes not defined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined a role for CD44 in transformed-cell survival by controlling COL17A1 membrane accumulation and suppressing mitochondrial-ROS-driven ferroptosis during cell extrusion.\",\n      \"evidence\": \"Plasma-membrane proteomics, COL17A1 knockout in RasV12 cells, metabolomics, and ROS/ferroptosis assays\",\n      \"pmids\": [\"34087104\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which CD44 stabilizes COL17A1 at the membrane not defined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established upstream transcriptional control of CD44, identifying an androgen-receptor silencer element that directly represses CD44 expression.\",\n      \"evidence\": \"AR ChIP-seq, transcriptomics, CRISPR mutagenesis of the androgen response element, and tumor expression correlation\",\n      \"pmids\": [\"33687952\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of AR-driven CD44 loss in vivo not fully defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CD44's diverse, context-specific signaling outputs (Wnt, Hippo, MAPK, TLR, phagocytosis, epigenetic plasticity) are selected by a single short cytoplasmic tail in a given cell type remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking ligand/glycosylation state to downstream pathway choice\", \"Structural basis of CD44-ICD transcriptional activity uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [0, 5, 13]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [6, 9, 7]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [8, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 3, 9]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 18]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 10, 16]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 6, 7]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [0, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [11, 16, 18]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LRP6\", \"TLR2\", \"IQGAP1\", \"ADAM10\", \"COL17A1\", \"GPNMB\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}